CDH2 and non-small cell lung carcinoma: MiR-302b-3p inhibits NSCLC progression by targeting glucosaminyl (N-acetyl) transferase 3 (GCNT3), with E-cadherin, N-cadherin, vimentin, phosphorylated-extracellular-signal-regulated kinase, and cyclin D1 being downstream molecules of the miR-302b-3p/GCNT3 pathway [72].